Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
As of today, Bristol-Myers Squibb(BMY) shares are valued at $55.92. The company's market cap stands at 113.86B, with a P/E ratio of 18.83 and a dividend yield of 4.4%.
As of 2026-01-13, Bristol-Myers Squibb(BMY) stock has fluctuated between $55.55 and $56.56. The current price stands at $55.92, placing the stock +0.7% above today's low and -1.1% off the high.
The Bristol-Myers Squibb(BMY)'s current trading volume is 10.92M, compared to an average daily volume of 11.93M.
In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.
In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.
BMY News
(RTTNews) - Bristol Myers Squibb (BMY) reported positive topline data from the Phase 3 SCOUT-HCM trial, the first randomized, placebo-controlled study of a card...
Claim 70% Off TipRanks Premium An announcement from Bristol-Myers Squibb ( (BMY) ) is now available. On January 12, 2026, Bristol Myers Squibb used its appear...
Bristol-Myers Squibb Company (BMY), Biontech Se Sponsored Adr (BNTX) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study...
Analyst ratings
60%
of 30 ratingsMore BMY News
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful...
Bristol-Myers Squibb recently secured approval for a new subcutaneous formulation of Opdivo, advanced its KarXT plus KarX-EC Phase 3 autism program, and reached...
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Bristol-Myers Squibb is...
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview Bristol-Myers Squibb (B...